Helus Pharma Inc. Common Stock HELP
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T14:55:57.222Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T14:55:43.739586403Z
FundamentalsAlpha Vantage · ready · quarter 2026-06-30 · fetched 2026-11-11T14:54:41.960571+00:00
Helus Pharma Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | ||||||
| 40Δ | ||||||
| 45Δ | 10.25 | 324.7% | 17.5% | |||
| 50Δ | ||||||
| 55Δ | 12.84 | 415.8% | 16.1% | |||
| 60Δ | 13.29 | 382.4% | 13.1% | |||
| 65Δ | 8.88 | 174.3% | 7.5% | 13.75 | 349.1% | 10.1% |
| 70Δ | 8.23 | 210.5% | 6.8% | 14.62 | 336.1% | 7.7% |
| 75Δ | 7.59 | 246.7% | 6.1% | 16.05 | 343.1% | 6.2% |
| 80Δ | 6.94 | 282.9% | 5.4% | 16.85 | 322.8% | 4.5% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.25
- IV
- 324.7%
- B/E move
- 17.5%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 12.84
- IV
- 415.8%
- B/E move
- 16.1%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 13.29
- IV
- 382.4%
- B/E move
- 13.1%
65Δ
- Pseudo strike
- 8.88
- IV
- 174.3%
- B/E move
- 7.5%
- Pseudo strike
- 13.75
- IV
- 349.1%
- B/E move
- 10.1%
70Δ
- Pseudo strike
- 8.23
- IV
- 210.5%
- B/E move
- 6.8%
- Pseudo strike
- 14.62
- IV
- 336.1%
- B/E move
- 7.7%
75Δ
- Pseudo strike
- 7.59
- IV
- 246.7%
- B/E move
- 6.1%
- Pseudo strike
- 16.05
- IV
- 343.1%
- B/E move
- 6.2%
80Δ
- Pseudo strike
- 6.94
- IV
- 282.9%
- B/E move
- 5.4%
- Pseudo strike
- 16.85
- IV
- 322.8%
- B/E move
- 4.5%
Options history
Table
| Date | IV (%) |
|---|---|
| 193.15% | |
| 191.12% | |
| 178.64% | |
| 188.73% | |
| 193.38% | |
| 207.13% | |
| 201.98% | |
| 199.92% | |
| 192.25% | |
| 198.27% |
Biotechnology
HOWL
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapies designed to boost the body's immune system for the treatment of cancer. The company is headquartered…
More →HRMY
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders. The company is…
More →HUMA
Humacyte Inc (HUMA) is a groundbreaking biotechnology firm at the forefront of vascular and regenerative medicine, specializing in the development of human acellular vessels…
More →IBRX
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
More →IDYA
Description unavailable
More →IFRX
InflaRx NV, a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company is…
More →